Evidence map›Paper›PMID 26475674›Full record

ArticleJournal of biochemistry2016

High-level expression and preparation of recombinant human fibrinogen as biopharmaceuticals.

Masaki Hirashima, Takayuki Imamura, Kentaro Yano, Ryoichi Kawamura, Akihiro Meta, Yoshiyuki Tokieda, Toshihiro Nakashima

Open access · bronzeAbstract read
In one paragraph

Article in Journal of biochemistry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.2field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Masaki HirashimaR&D Division; and.
Takayuki ImamuraR&D Division; and.
Kentaro YanoBlood Plasma Division, The Chemo-Sero-Therapeutic Research Institute, KAKETSUKEN, 1314-1 Kyokushi-Kawabe, Kikuchi, Kumamoto 869-1298, Japan.
Ryoichi KawamuraR&D Division; and.
Akihiro MetaR&D Division; and.
Yoshiyuki TokiedaBlood Plasma Division, The Chemo-Sero-Therapeutic Research Institute, KAKETSUKEN, 1314-1 Kyokushi-Kawabe, Kikuchi, Kumamoto 869-1298, Japan.
Toshihiro NakashimaR&D Division; and nakashima-to@kaketsuken.or.jp.
Research & Development Establishment (Engrs.) · INKaketsuken (Japan) · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fibrinogen is a large and complex glycoprotein containing two sets of each of three different chains (α, β and γ). There have been no reports of high-level expression of fibrinogen at commercial levels using mammalian cultured cells such as CHO cells because of the difficulty in highly expressing a protein with such a complex structure. We achieved high-level (1.3 g/l or higher) expression of recombinant human fibrinogen using CHO DG44 cells by optimizing the expression system and culture conditions. We also succeeded in establishing a high-recovery preparation method for recombinant fibrinogen that rarely yields degraded products. To characterize the properties of the recombinant human fibrinogen, we performed SDS-PAGE; western blotting of the α, β and γ chains using specific antibodies and scanning electron microscopy observations of fibrin fibres. We also evaluated the functional equivalence between recombinant fibrinogen and plasma fibrinogen with respect to the release of fibrinopeptides initiated by thrombin and its cross-linking properties. The basic properties of recombinant fibrinogen showed no apparent differences from those of plasma fibrinogen. Here, we report the development of methods for the culture and preparation of recombinant human fibrinogen of satisfactory quality that can be scaled up to the commercial level.

Indexed as

AnimalsBiological ProductsBlotting, WesternCHO CellsCricetinaeCricetulusElectrophoresis, Polyacrylamide GelFibrinFibrinogenHumansMicroscopy, Electron, ScanningRecombinant ProteinsThrombinBiological ProductsFibrinFibrinogenRecombinant ProteinsThrombinbiopharmaceuticalsCHO DG44high-level expressionhigh-recovery preparationrecombinant human fibrinogen

Identifiers

PMID26475674
PMCPMC4892781
OpenAlexW2267751458

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.